打开APP

Atara第二轮融资5200万美元用于支持癌症和肾病研究

  1. Atara
  2. 卵巢癌
  3. 肾病

来源:生物谷 2014-01-13 08:53

2014年1月13日讯 /生物谷BIOON/ --加州的生物技术公司Atara Biotherapeutics最近进行了第二轮融资用于其肾病和肿瘤学的研究。而就在上个月,公司刚刚收获了来自Celgene、拜耳等公司总额达1350万美元的资金用于研发两种处于临床阶段的新药。PINTA 745是一种多肽抗体药物,这种药物主要用于患有肾病的患者蛋白能量浪费的症状,这一药物目前正处于临床二期研究阶段。STM 434则是通过阻断激活素来治疗卵巢癌的药物。除了这两种处于临床阶段的药物之外,Atara公司还拥有一项临床前研究的药物NINA842。这一药物主要是用于治疗因癌症而引起的体重急速减少。公司计划通过这两轮融资获得7200万美元以保证未来两年公司研究项目的正常进行。(生物谷Bioon.com)

详细英文报道:

California's Atara Biotherapeutics has heaped more cash onto its second funding round, giving the Amgen ($AMGN) spinoff $52 million in Series B funds to support its programs in kidney disease and oncology.

Last month, the biotech hauled in $38.5 million from the likes of Celgene ($CELG), Kleiner Perkins Caulfield & Byers, Domain Associates and ex-parent Amgen. Now Its investors have come back around for a second closing, adding $13.5 million to the sum to help Atara push its two lead candidates through clinical development, and the company is expecting to churn out new data on both in the next 18 months.

PINTA 745, Atara's most advanced drug, is a Phase II peptide-antibody combo that inhibits myostatin in order to fight protein energy wasting, an inflammatory ailment that afflicts patients with end-stage renal disease. Next is STM 434, which is a Phase I-ready oncology therapy that inhibits activin to kill off ovarian cancer and other solid tumors. Finally, in keeping with its Columbian theme, Atara is developing NINA 842, a preclinical myostatin-targeting antibody designed to combat cancer-related weight loss.

The second close brings Atara's two-year haul to $72 million, and CEO Isaac Ciechanover plans to maintain a lean operation and dump the vast majority of that cash into clinical development. Atara maintains a tiny team of 6, and that efficient structure allows the biotech to be flexible with its focus, Ciechanover told FierceBiotech last month.

The company got its start in 2012 when Amgen and Kleiner Perkins agreed to pair one's preclinical assets with the other's cash and get Atara off the ground. Amgen handed over 6 early-stage molecules in the deal, and the company maintains an equity stake in its spinoff.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->